LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the ...

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Novo Nordisk A/S ADR (NVO-N) NYSE Add to Watchlist Create Alerts 126.99 USD +0.53 +0.42% Real-Time Last Update 04/03/24 Last Sale Cboe BZX Real-Time Volume 3,609,254 Summary Charts Profile ...

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

By Sam Boughedda Jefferies analysts initiated Eli Lilly & Co. (NYSE: LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE: MRK) with a Buy rating and $125 price target in ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...